Four Health Systems Automated the Prior Authorization Question, Not the Answer Athithi Verma August 19, 2026 The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything. Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold. OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard Editor’s Pick In Japan, Expanding a Label Is What Triggers the Price Cut AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway. Congress Exempted the Medically Frail. The Coding System Cannot Find Them.NeuroPulse NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It YetOrphanPulse OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029DealPulse Signal DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of ItDealPulse Report DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174BThe Beats DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the LeadAnalysis 7 Market Access Trends Reshaping Pharmaย by 2027 The Biologics Patent Cliff: Inside Pharma’s 2026-2029 ReckoningCoverage The ADC Decade Accelerates: What to Watch at ASCO 2026The Briefs Four Health Systems Automated the Prior Authorization Question, Not the Answer Athithi Verma August 19, 2026 Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It Athithi Verma August 19, 2026 CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma August 19, 2026 A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold. Athithi Verma August 19, 2026 ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma August 18, 2026 Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision. Athithi Verma August 18, 2026 Read More
Four Health Systems Automated the Prior Authorization Question, Not the Answer Athithi Verma August 19, 2026 The piece of the federal prior authorization mandate that shipped five months early is the piece that cannot deny anything.
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route
Four Health Systems Automated the Prior Authorization Question, Not the Answer Athithi Verma August 19, 2026
Novartis Declines Canadian Reimbursement for Vanrafia Five Weeks After Health Canada Approved It Athithi Verma August 19, 2026
CMS Comments Close on a Rule That Retires the Small Biotech Exemption and Shuts the Hyaluronidase Route Athithi Verma August 19, 2026
A Third Centiloid Scale Just Cleared. The First Two Already Disagree at the Threshold. Athithi Verma August 19, 2026
ViGNet Reported 82.55% Discrimination Predicting Immunotherapy Response in NSCLC Athithi Verma August 18, 2026
Payers Do Not Cover Wellness. In Women’s Health, That Is a Naming Decision. Athithi Verma August 18, 2026